Compare IMUX & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
| Metric | IMUX | NEN |
|---|---|---|
| Founded | 2016 | 1977 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.8M | 209.2M |
| IPO Year | 2013 | 1995 |
| Metric | IMUX | NEN |
|---|---|---|
| Price | $14.17 | $58.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 232.3K | 600.0 |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $89,196,544.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.68 |
| Revenue Growth | N/A | ★ 10.76 |
| 52 Week Low | $0.51 | $56.00 |
| 52 Week High | $15.77 | $74.48 |
| Indicator | IMUX | NEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 44.85 |
| Support Level | $0.74 | $56.50 |
| Resistance Level | $15.77 | $60.90 |
| Average True Range (ATR) | 1.18 | 0.86 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 69.09 | 38.46 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.